Claritas Pharmaceuticals, Inc. Stock

CLAZF

CA1806342061

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 12:16:04 2026-02-27 pm EST			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-

Valuation: Claritas Pharmaceuticals, Inc.

Market Cap	5.37M 3.85M 3.33M 3.11M 2.85M 367M 5.45M 36.5M 14.33M 184M 14.46M 14.15M 607M	P/E 2019	-0.74x	P/E 2020	0.13x
Enterprise Value	6.29M 4.51M 3.9M 3.64M 3.34M 429M 6.39M 42.76M 16.78M 215M 16.94M 16.57M 712M	EV / Sales 2019	-	EV / Sales 2020	-
Free-Float	99.74%	Yield 2019 *	-	Yield 2020	-

* Estimated data More valuation ratios

Chart: Claritas Pharmaceuticals, Inc.

Dynamic Chart

Managers and Directors: Claritas Pharmaceuticals, Inc.

Manager	Title	Age	Since
Robert Farrell CEO	Chief Executive Officer	76	2017-06-20
Victoria Rudman DFI	Director of Finance/CFO	58	2018-06-28

Director	Title	Age	Since
Robert Farrell CHM	Chairman	76	2021-03-17

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CLARITAS PHARMACEUTICALS, INC.	-.--%	-.--%	-	-	37
LONZA GROUP AG	+0.99%	+1.78%	+5.07%	+16.49%	49.47B
REVOLUTION MEDICINES, INC.	+3.71%	+9.40%	+486.14%	+579.98%	43.61B
BEONE MEDICINES AG	+5.60%	+10.21%	+20.85%	+81.78%	39.6B
IQVIA HOLDINGS INC.	+2.70%	+1.57%	+32.71%	+9.07%	39.29B
CELLTRION, INC.	+2.21%	+6.75%	+20.20%	+54.40%	32.43B
ASCENDIS PHARMA A/S	+2.23%	+4.71%	-	-	16.84B
MEDPACE HOLDINGS, INC.	+0.97%	+2.35%	+35.99%	+124.45%	16.49B
EUROFINS SCIENTIFIC SE	-0.11%	+2.41%	+5.03%	+20.47%	14.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.75%	+15.04%	+79.84%	+29.70%	12.77B
Average	+1.90%	+5.69%	+85.73%	+114.54%	26.45B
Weighted average by Cap.	+2.54%	+6.10%	+104.59%	+138.04%

See all sector performances

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Companyâ€™s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
CLAZF Stock

As early as today, start finding the best investment opportunities!

Maximize my profits

Current year	0		0
1 year	0		0
3 years	0		0
5 years	0		0.4
10 years	0		15.31

Date	Insider	Type	Quantity	% Market Cap.
10/11/21	Andrew Salzman	Buy	118,000	0.3332%
10/11/21	Andrew Salzman	Buy	152,500	0.4307%
10/11/21	Andrew Salzman	Buy	24,500	0.0692%

	2019	2020
Net sales	-	-
Net income	-21.21M -15.22M -13.16M -12.29M -11.28M -1.45B -21.55M -144M -56.61M -726M -57.15M -55.9M -2.4B	4.21M 3.02M 2.61M 2.44M 2.24M 287M 4.28M 28.63M 11.24M 144M 11.34M 11.09M 476M
Net Debt	704K 505K 437K 408K 374K 48.07M 715K 4.79M 1.88M 24.09M 1.9M 1.86M 79.66M	920K 660K 571K 533K 489K 62.82M 935K 6.26M 2.46M 31.49M 2.48M 2.42M 104M

Claritas Pharmaceuticals, Inc. Stock

Stocks

CLAZF

CA1806342061

Biotechnology & Medical Research

Valuation: Claritas Pharmaceuticals, Inc.

Chart: Claritas Pharmaceuticals, Inc.

Course Extremes

Managers and Directors: Claritas Pharmaceuticals, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile